Live price temporarily unavailable.
Artiva Biotherapeutics (ARTV) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $33.5M | $251.0K | $0 |
| Growth (year over year) | — | −99.3% | −100.0% |
| Operating income | −$30.7M | −$67.3M | −$89.8M |
| Operating margin | −91.6% | −26805.6% | — |
| Net income | −$28.7M | −$65.4M | −$83.9M |
| Net margin | −85.8% | −26045.0% | — |
| EPS (diluted) | −$35.78 | −$5.81 | −$3.43 |
| Balance sheet | |||
| Cash and equivalents | $53.5M | $40.2M | $26.7M |
| Total assets | $105.1M | $209.6M | $130.9M |
| Total liabilities | $50.7M | $22.9M | $21.0M |
| Shareholders' equity | −$162.0M | $186.6M | $110.0M |
| Cash flow | |||
| Operating cash flow | −$47.4M | −$55.0M | −$76.8M |
| Capital expenditure | $3.26M | $642.0K | $2.59M |
| Free cash flow | −$50.7M | −$55.7M | −$79.3M |
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Growth (year over year) | −100.0% | — | — | — | — | — | — | — |
| Operating income | −$18.3M | — | −$22.2M | −$22.8M | −$22.9M | −$21.9M | −$24.4M | −$26.9M |
| Net income | −$17.5M | — | −$20.3M | −$21.3M | −$21.5M | −$20.8M | −$23.5M | −$25.0M |
| EPS (diluted) | −$0.92 | — | −$0.83 | −$0.87 | −$0.88 | −$0.85 | −$0.95 | −$0.63 |
| Balance sheet | ||||||||
| Cash and equivalents | $55.9M | $40.2M | $30.4M | $28.5M | $25.5M | $26.7M | $21.0M | $301.5M |
| Total assets | $225.6M | $209.6M | $191.3M | $169.4M | $148.9M | $130.9M | $106.0M | $368.6M |
| Total liabilities | $24.6M | $22.9M | $22.5M | $20.4M | $19.6M | $21.0M | $18.1M | $21.1M |
| Shareholders' equity | $201.0M | $186.6M | $168.8M | $149.0M | $129.2M | $110.0M | $87.8M | $347.5M |
| Cash flow | ||||||||
| Operating cash flow | −$11.6M | — | −$19.8M | −$23.0M | −$19.2M | −$14.7M | −$20.9M | −$20.4M |
| Capital expenditure | $96.0K | — | $511.0K | $1.05M | $600.0K | $421.0K | $242.0K | $415.0K |
| Free cash flow | −$11.7M | — | −$20.4M | −$24.0M | −$19.8M | −$15.1M | −$21.2M | −$20.8M |
From Artiva Biotherapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Artiva Biotherapeutics in our feed yet.